AROUND THE REGION
BILLERICA — Biotech equipment maker Millipore Corp. said yesterday that its shareholders have approved the company’s $6 billion sale to the German drug and chemical maker Merck KGaA.
The $107-per-share deal was announced in February and represented about a 50 percent premium to the company’s stock price before buyout speculation. Including assumed debt, Merck KGaA values the deal at $7.2 billion.
Millipore said holders of about 79 percent of the company’s outstanding shares voted at the special meeting, with about 98 percent of them favoring the deal.
The transaction is expected to be completed early in the third quarter, pending antitrust clearance.
© Copyright 2010 Globe Newspaper Company.
